COMMUNIQUÉS West-GlobeNewswire

VALNEVA Reports Strong Q1 2019 Operating Results and Advances Key R&D Programs towards Major Milestones
02/05/2019
Valneva Reports Strong Q1 2019 Operating Results and Advances Key R&D Programs towards Major Milestones Repeated significant growth in IXIARO ® revenues; Lyme disease and chikungunya programs advancing towards major [...]
VALNEVA : très bons résultats opérationnels au T1 2019, avancée des programmes clés vers d'importants jalons R&D
02/05/2019
Valneva : très bons résultats opérationnels au T1 2019, avancée des programmes clés vers d'importants jalons R&D Croissance significative et répétée des ventes d'IXIARO ® ; Avancée des programmes contre la maladie [...]
Lloyd Diamond will serve as Chief Executive Officer of Pixium Vision
02/05/2019
Paris, May 2 nd , 2019 – 07:00 AM CEST - Pixium Vision (FR0011950641 - PIX), a bioelectronics company developing innovative bionic vision systems to enable patients who have lost their sight to lead more independent [...]
Lloyd Diamond sera nommé Directeur Général de Pixium Vision
02/05/2019
Paris, 2 mai 2019 – 07 : 00 CEST - Pixium Vision (FR0011950641 - PIX), société bioélectronique qui développe des systèmes de vision bionique innovants pour permettre aux patients ayant perdu la vue de vivre de façon [...]
Genkyotex Reports Clinical Evidence of Anti-fibrotic Activity by GKT831 in Liver Fibrosis Patients
02/05/2019
Top Line Efficacy Results from Phase 2 Primary Biliary Cholangitis (PBC) Trial 22% reduction in liver stiffness in PBC patients with liver fibrosis compared to a 4% increase for placebo (p=0.038), supports anti-fibrotic [...]
Genkyotex communique sur les données cliniques attestant d'une activité anti-fibrotique du GKT831 chez des patients atteints de fibrose hépatique
02/05/2019
ERN France, 02 mai 2019 (GLOBE NEWSWIRE) -- Genkyotex communique sur les données cliniques attestant d'une activité anti-fibrotique du GKT831 chez des patients atteints de fibrose hépatique
TransMedics Announces Pricing of Upsized Initial Public Offering
02/05/2019
ANDOVER, Mass., May 01, 2019 (GLOBE NEWSWIRE) -- TransMedics Group, Inc., a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, (“ [...]
Precipio Reminder of Corporate Update Shareholder Call
02/05/2019
Conference Call to be held Monday May 6th, 2019 at 5:00pm Eastern Time NEW HAVEN, Conn., May 01, 2019 (GLOBE NEWSWIRE) -- Specialty diagnostics company Precipio, Inc. ( NASDAQ: PRPO ), will host a conference call on [...]
Tetra Bio-Pharma Closes the Acquisition of Panag Pharma
01/05/2019
OTTAWA, May 01, 2019 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc. (" Tetra " or the " Company "), a leader in cannabinoid-based drug discovery and development (TSX VENTURE: TBP) (OTCQB: TBPMF), is pleased to announce that [...]
Zogenix Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
01/05/2019
EMERYVILLE, Calif., May 01, 2019 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that it has issued inducement awards to nine new non- [...]
Flexion Therapeutics to Report First-Quarter 2019 Financial Results on May 8, 2019
01/05/2019
BURLINGTON, Mass., May 01, 2019 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it will report its first-quarter 2019 financial results after the close of the U.S. financial markets on [...]
Innovate Biopharmaceuticals Announces Closing of $8.7 Million Registered Direct Offering
01/05/2019
RALEIGH, N.C., May 01, 2019 (GLOBE NEWSWIRE) -- Innovate Biopharmaceuticals, Inc. (NASDAQ: INNT) today announced the closing of its previously announced registered direct offering of 4,318,272 shares of common stock at [...]
Sarepta Therapeutics to Announce First Quarter 2019 Financial Results and Recent Corporate Developments on May 8, 2019
01/05/2019
CAMBRIDGE, Mass., May 01, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report first quarter 2019 financial results after the Nasdaq [...]
Biogen to Present New Interim Data from Its Phase 1/2 Clinical Study of Tofersen (BIIB067) for the Potential Treatment of a Subtype of Familial Amyotrophic Lateral Sclerosis (ALS)
01/05/2019
Tofersen, an antisense oligonucleotide (ASO) that selectively targets the genetic driver of disease, is being studied for the potential treatment of ALS in adults with a confirmed superoxide dismutase 1 (SOD1) mutation [...]
CMS Issues Preliminary Recommendation to Establish a New J-Code for Triferic® Powder Packet
01/05/2019
--Final CMS Decision Anticipated Later This Year-- WIXOM, Mich., May 01, 2019 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ:RMTI) (the "Company"), a global biopharmaceutical company dedicated to improving outcomes [...]
Veloxis to Host Conference Call Following Release of Interim Financial Report for the Period 1 January to 31 March 2019
01/05/2019
Investor News no. 02/2019 To: NASDAQ Copenhagen A/S Copenhagen, Denmark, 1 May 2019 Veloxis to Host Conference Call Following Release of Interim Financial Report for the Period 1 January to 31 March 2019 Veloxis [...]
Kalytera Reports 2018 Financial Results
01/05/2019
SAN FRANCISCO and TEL AVIV, Israel, May 01, 2019 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the " Company " or " Kalytera ") today reported financial results for the year ended [...]
Ziopharm Oncology to Host Conference Call to Discuss First Quarter 2019 Financial Results on May 8, 2019
01/05/2019
BOSTON, May 01, 2019 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (Nasdaq:ZIOP) today announced that management will host a conference call and webcast on Wednesday, May 8, at 4:30 p.m. ET to provide a corporate update [...]
Inovalon Reports First Quarter 2019 Results
01/05/2019
First Quarter 2019 Highlights Q1 revenue of $145.5 million, up 57% year-over-year Q1 net loss of $8.3 million, resulting in net loss of $0.06 per share Q1 Non-GAAP net income of $14.7 million, resulting in Non-GAAP net [...]

Pages